Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Track-And-Trace Will Not Hitch A Ride On The User Fee Train

This article was originally published in The Pink Sheet Daily

Executive Summary

Efforts to reach a consensus proposal have been unsuccessful as the bill nears a possible final vote in the House.

You may also be interested in...



Rx Supply Chain Bill On Track In Senate; Will House Use The Same Gauges?

Track-and-trace measure goes to floor coupled to compounding bill, but the all-smiles markup in the Senate HELP Committee is more than made up for by the differences that remain with the House version.

Track and Trace: Draft Senate Bill Requires Unit-level System In 10 Years; House Opts For Study

The difference in approach to unit-level tracing underscores the difficulty supporters of a national track-and-trace program face in gaining final approval of a bill before manufacturers go too far down the road in implementing a California pedigree law that goes into effect in 2015.

Draft Guidances For 2013 Will Grapple With Biosimilars, Track and Trace, Compounding

FDA’s Center for Drug Evaluation and Research plans to publish more than 50 new and revised draft guidances this calendar year.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS074297

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel